Stock Events

Stock Events

Pasithea Therapeutics 

$0.007400
19
+$0.00+0% Wednesday 15:51
+$0.00+0%Wednesday 20:00After hours

Statistics

Day High
0.0074
Day Low
0.0035
52W High
0.0074
52W Low
0.0035
Volume
10,900
Avg. Volume
-
Mkt Cap
247,266.92
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

2DecExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.66
-0.48
-0.3
-0.12
Expected EPS
-0.21
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-20.43MNet Income

Analyst Ratings

3.00Average Price Target
The highest estimate is 3.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow KTTAW. It's not an investment recommendation.
Tesla
6
TSLA
NVIDIA
6
NVDA
Riot Platforms
6
RIOT
Realty Income
5
O

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Axsome Therapeutics
AXSM
Mkt Cap10.42B
Axsome Therapeutics develops novel therapies for central nervous system disorders, overlapping with Pasithea's focus.
BridgeBio Pharma
BBIO
Mkt Cap14.97B
BridgeBio Pharma targets genetic diseases and cancers, including neurological disorders, competing with Pasithea's approach.
Alkermes
ALKS
Mkt Cap7.95B
Alkermes plc works on central nervous system diseases, including depression and schizophrenia, areas of interest for Pasithea.
Acadia Pharmaceuticals
ACAD
Mkt Cap5.02B
ACADIA Pharmaceuticals specializes in central nervous system disorders, making it a direct competitor.
Biogen
BIIB
Mkt Cap32.28B
Biogen focuses on neurodegenerative diseases, directly competing with Pasithea's focus on mental health and neurological disorders.
AMGEN
AMGN
Mkt Cap233.78B
Amgen's broad focus on innovative therapeutics includes work on central nervous system disorders.
Jazz Pharmaceuticals
JAZZ
Mkt Cap15.87B
Jazz Pharmaceuticals has a portfolio that includes treatments for psychiatric disorders, competing in Pasithea's market.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap42.46B
Teva Pharmaceutical Industries offers generic and specialty medicines, including CNS treatments, making it a competitor.
Novartis
NVS
Mkt Cap292.35B
Novartis AG, with its extensive research in neuroscience, competes in developing treatments for disorders targeted by Pasithea.

About

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.
Show more...
CEO
Tiago Reis Marques
Employees
5
Country
United States
ISIN
US70261F1113

Listings

BOATS
BOATS
KTTA.BOATS
XNAS
US
KTTAW
XNAS
US
KTTA

0 Comments

Share your thoughts

FAQ

What is Pasithea Therapeutics stock price today?▼
The current price of KTTAW is $0.01 USD — it has increased by +0% in the past 24 hours. Watch Pasithea Therapeutics stock price performance more closely on the chart.
What is Pasithea Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Pasithea Therapeutics stocks are traded under the ticker KTTAW.
What is Pasithea Therapeutics market cap?▼
Today Pasithea Therapeutics has the market capitalization of 247,266.92
When is the next Pasithea Therapeutics earnings date?▼
Pasithea Therapeutics is going to release the next earnings report on December 02, 2026.
What is Pasithea Therapeutics revenue for the last year?▼
Pasithea Therapeutics revenue for the last year amounts to 0 USD.
What is Pasithea Therapeutics net income for the last year?▼
KTTAW net income for the last year is -20.43M USD.
How many employees does Pasithea Therapeutics have?▼
As of September 05, 2026, the company has 5 employees.
In which sector is Pasithea Therapeutics located?▼
Pasithea Therapeutics operates in the Health & Wellness sector.
When did Pasithea Therapeutics complete a stock split?▼
The last stock split for Pasithea Therapeutics was on January 02, 2024 with a ratio of 1:20.
Where is Pasithea Therapeutics headquartered?▼
Pasithea Therapeutics is headquartered in MIAMI BEACH, United States.